Literature DB >> 27573704

Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time.

Rebecca L Mercieca-Bebber1,2, Melanie A Price2,3, Melanie L Bell2,4, Madeleine T King1,2, Penelope M Webb5, Phyllis N Butow2,3.   

Abstract

AIMS: Participant drop out is a major barrier to high-quality patient-reported outcome (PRO) data analysis in cancer research as patients with worsening health are more likely to dropout. To test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia.
METHODS: This analysis included 619 participants, stratified by time of dropout, from the Australian Ovarian Cancer Study - Quality of Life substudy, in which participants completed PRO questionnaires at three-monthly intervals for 21 months. Trends in PROs over time were examined. Pearson correlations examined the relationship between time of dropout and baseline PROs. Multiple linear regression models including age, disease stage and time since diagnosis examined relationships between baseline and final PRO scores, and final PRO scores and dropout group.
RESULTS: Participants who dropped out earlier had significantly worse baseline HRQOL (p < 0.0001) and higher depression (p < 0.0001). For all five PROs, final scores were significantly associated with baseline scores (p < 0.0001). Time of dropout was significantly associated with final HRQOL (p = 0.003), anxiety (p = 0.05), depression (p = 0.02) and optimism (p = 0.02) scores. Depression, HRQOL and anxiety worsened at a faster rate overtime in dropouts than study completers.
CONCLUSIONS: Poorer HRQOL and higher depression at baseline, and final HRQOL, anxiety, depression and optimism scores were predictive of time of dropout. These results highlight the importance of collecting auxiliary data to inform careful and considered handling of missing PRO data during analysis, interpretation and reporting.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  depression; ovarian neoplasms; patient outcome assessment; quality of life

Mesh:

Year:  2016        PMID: 27573704     DOI: 10.1111/ajco.12580

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

1.  Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review.

Authors:  Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King
Journal:  Qual Life Res       Date:  2020-09-22       Impact factor: 4.147

2.  A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice.

Authors:  Rebecca Mercieca-Bebber; Michael Friedlander; Melanie Calvert; Martin Stockler; Derek Kyte; Peey-Sei Kok; Madeleine T King
Journal:  J Patient Rep Outcomes       Date:  2017-10-04

3.  Did psychosocial status, sociodemographics and smoking status affect non-attendance in control participants in the Danish Lung Cancer Screening Trial? A nested observational study.

Authors:  Jessica Malmqvist; Volkert Siersma; Hanne Thorsen; Bruno Heleno; Jakob Fraes Rasmussen; John Brodersen
Journal:  BMJ Open       Date:  2020-02-20       Impact factor: 2.692

4.  Cancer survivors who fully participate in the PROFILES registry have better health-related quality of life than those who drop out.

Authors:  Imogen Ramsey; Belle H de Rooij; Floortje Mols; Nadia Corsini; Nicole J E Horevoorts; Marion Eckert; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2019-09-06       Impact factor: 4.442

5.  Strategies to improve patient-reported outcome completion rates in longitudinal studies.

Authors:  Lene Kongsgaard Nielsen; Madeleine King; Sören Möller; Mary Jarden; Christen Lykkegaard Andersen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Bo Amdi Jensen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard
Journal:  Qual Life Res       Date:  2019-09-23       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.